Who’s Afraid Of Payment Reform? CMS Cardiac Bundle Shows How Changes Can Be Positive For Rx
Executive Summary
Medicare’s proposed demonstration project to change payments in Medicare Part B aside, when it comes to ideas for payment and delivery reform, prescription drugs should do pretty well. CMS’ new proposal to bundle cardiac payments is a timely case in point.
You may also be interested in...
Part B Demo Comments Overwhelmingly Negative, Uniform In Content
More than 90% of comments submitted on proposed Medicare payment experiment for Part B drugs were negative, and most were submitted by patients and health care providers.
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.